MedPath

Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure

Phase 2
Conditions
Heart Failure
Ketosis
Interventions
Dietary Supplement: KetoneAid KE4 Pro Monoester
Dietary Supplement: Science in Sport Go Enegy
Registration Number
NCT04594265
Lead Sponsor
University of Aarhus
Brief Summary

We aim to investigate the hemodynamic effects of weight-adjusted dosing of ketone monoester en patients with chronic heart failure.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
8
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Diabetes or HbA1c >48 mmol/mol, significant cardiac valve disease, severe stable angina pectoris, severe comorbidity as judged by the investigator, inability to give informed consent

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Ketone MonoesterKetoneAid KE4 Pro MonoesterWeight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)
Placebo TreatmentScience in Sport Go EnegyMaltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.
Ketone Monoester in presence of low-dose insulin clampKetoneAid KE4 Pro MonoesterSame as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism
Primary Outcome Measures
NameTimeMethod
Cardiac Output (L/min)3 hours - Area under the curve

Change in Cardiac output measured by Swann-Ganz Catherization during study period,

Secondary Outcome Measures
NameTimeMethod
Blood Ketones3 hours

Change in blood Ketones measured by venous blood samples

Blood pH3 hours

Change in venous blood pH during the study period

Left Ventricular Ejection Fraction3 hours - Area under the curve

Change in LVEF measured by echocardiography during study periode

Trial Locations

Locations (1)

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath